Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAFV600 mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysis.
about
Global view of a drug-sensitivity gene network.Contemporary outcomes from the use of regular imaging to detect relapse in high-risk cutaneous melanoma.Vemurafenib in Langerhans cell histiocytosis: report of a pediatric patient and review of the literature.The Role of Human Papillomaviruses and Polyomaviruses in BRAF-Inhibitor Induced Cutaneous Squamous Cell Carcinoma and Benign Squamoproliferative Lesions
P2860
Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAFV600 mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysis.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
Open-label, multicentre safety ...... ong-term responders' analysis.
@ast
Open-label, multicentre safety ...... ong-term responders' analysis.
@en
type
label
Open-label, multicentre safety ...... ong-term responders' analysis.
@ast
Open-label, multicentre safety ...... ong-term responders' analysis.
@en
prefLabel
Open-label, multicentre safety ...... ong-term responders' analysis.
@ast
Open-label, multicentre safety ...... ong-term responders' analysis.
@en
P2093
P50
P1476
Open-label, multicentre safety ...... long-term responders' analysis
@en
P2093
Axel Hauschild
Christian U Blank
Enrique Espinosa
Geke A P Hospers
Helen Gogas
Jacob Schachter
James Larkin
Mario Mandalà
Martina Makrutzki
Michael P Brown
P304
P356
10.1016/J.EJCA.2017.04.007
P577
2017-05-11T00:00:00Z